BIO Common Stock · Transaction Nov 3, 2023 · Filed Dec 6, 2023 · Amount pending receipt enrichment
Bio Rad Laboratories Inc
Veridion Score
BETAHIGH CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is BIO moving today?
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
BIO overview
Related filings and maps
Congress activity in BIO
BIO Common Stock · Transaction Oct 26, 2023 · Filed Nov 8, 2023 · Amount pending receipt enrichment
BIO Common Stock · Transaction Oct 2, 2023 · Filed Nov 8, 2023 · Amount pending receipt enrichment
BIO · Transaction Sep 8, 2023 · Filed Oct 10, 2023 · $1,001 to $15,000
BIO Common Stock · Transaction Jun 29, 2023 · Filed Jul 11, 2023 · Amount pending receipt enrichment
BIO contract awards, year to date.
Public federal awards linked to this ticker.
BIO lobbying filings, year to date.
Registered lobbying filings matched to Bio Rad Laboratories Inc.
FORBES-TATE
FORBES-TATE
FORBES-TATE